Vital Therapies (NASDAQ:VTL) appointed Faheem Hasnain to the board, effective immediately.
Mr. Hasnain served as president, CEO and as a director of Receptos from November 2010 to August 2015, when it was purchased by Celgene for $7.8-billion. He is currently chairman of Tocagen and Sente.
“Faheem’s strong track record in biotechnology drug development will be extremely valuable as we continue executing on our current Phase 3 trial, VTL-308,” Muneer Satter, co-chairman, said in a statement.
Mr. Hasnain said he believes ELAD is a promising therapy addressing an important unmet need and looks forward to helping guide its development and potential commercialization.